Authors

Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint

Recent policy shifts in these two influential health technology assessment markets signal a broader regional move toward faster, more innovation-friendly access frameworks.

Navigating Cross-Border Pharma Deals: Key Trends and Lessons Out of China

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

Transforming Life Sciences R&D: The Business Case for AI

Webinar Date/Time: Thu, Aug 14, 2025 3:30 PM EDT

JCA vs. Reality: Europe’s Push for Clinical Harmonization

Europe’s Joint Clinical Assessment promises harmonization, but it introduces a new layer of strategic complexity that manufacturers must navigate at both EU and national levels.

Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for Executives

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.

How Agentic AI Is Reshaping the Launch Playbook for Pharma

The agentic model is emerging as a strategic tool to compress analysis timelines, coordinate cross-functional teams and surface competitive intelligence in real time.

Taking Advantage of ‘Hidden Gem’ Talent Hubs

How to optimize a pharma location strategy in unheralded but rich regions for biotech talent around the world.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

How to Overcome Supply Chain Constraints and Enable Growth for Cell & Gene Therapies

Krystal Haynes, Senior Director of Business Development, ICS, at Cencora, outlines the challenges facing cell and gene therapy manufacturers as they attempt to move products from clinical development to commercial availability.

Navigating the EU’s Joint Clinical Assessment

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be critical.

From Blockbusters to Black Holes: Pharma Launch Strategy in the Age of Technology and AI

Pharma Forecasting: Key Markets Investors Can’t Ignore

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

Driving Field Excellence with AI-Enhanced Rep Support

JCA vs. Reality: Europe’s Push for Clinical Harmonization

Europe’s Joint Clinical Assessment promises harmonization, but it introduces a new layer of strategic complexity that manufacturers must navigate at both EU and national levels.

Being Specific About Being General: Vaccines Edition

Christopher Locher, PhD, CEO, Versatope Therapeutics, Inc., discusses how emerging vaccine platforms are advancing the pursuit of a universal influenza vaccine, while highlighting the scientific, regulatory, and economic barriers that continue to shape its path to reality.

Pharmaceutical Executive Daily: FDA Approves Datroway

In today’s Pharmaceutical Executive Daily, the FDA approves Datroway for certain patients with metastatic triple-negative breast cancer, leadership changes continue at the National Institutes of Health with the departure of a top infectious disease institute director, and industry experts discuss how real-time data is reshaping biotech decision-making and development strategy.

AI-Enabled Benchmarking: Transforming Performance Measurement for Pharma Brands

Market dynamics boost the need and urgency for more sophisticated benchmarking strategies.

The RWE Backlog Problem

JCA vs. Reality: Europe’s Push for Clinical Harmonization

Europe’s Joint Clinical Assessment promises harmonization, but it introduces a new layer of strategic complexity that manufacturers must navigate at both EU and national levels.

Driving Field Excellence with AI-Enhanced Rep Support

Are DTC Programs Treating a Symptom or Cause of High Drug Prices?

Jesse Mendelsohn, executive vice president at Model N, discusses the broader issues impacting drug prices.

Abu Dhabi Reinforces Global Leadership in Healthcare Innovation with High-Level US Visit

During a high-level US visit, the Department of Health—Abu Dhabi signed strategic agreements with Abbott, Boehringer Ingelheim, and Sanofi to boost pharmaceutical manufacturing, expand vaccine development, and advance digital health and clinical research.

Consent‑Driven Targeting: Building Trust With Patients and HCPs

From data risk to relationship equity, the need to rethink consent in life sciences marketing.

How Pharma’s Checks and Balances Can Help Fight Its Public Perception

What can we do to prevent such blatant black eyes to the industry so many of us love?

Cautious Momentum: Biopharma Review and Outlook

Fresh off 2025, where the sectors delivered strong stock gains and selective financing momentum despite volatile markets, companies navigate policy headwinds, patent cliffs, and shifting global innovation dynamics, factors that favor strategically driven growth pursuits ahead.

The Prior Authorization System Fails Patients. There's a Better Way

How existing technologies and approaches such as targeted AI deployment can help make prior authorization workflows more efficient.

Future-Proofing CRM Investments in Life Sciences: Observations from Dreamforce 2024

The future is bright with AI-powered innovations, but migration presents significant risks, including data loss, increased costs, and disruption to business operations.

Industrializing Machine Learning and Artificial Intelligence in Life Sciences

Life science organizations that will lead the next decade ar those that deploy systems that are scientifically credible, clinically defensible, regulatorily traceable, and operationally sustained.

ROI and Rare Disease: Retooling the ‘Gene’ Value Machine

Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.